WallStSmart

RLX Technology Inc (RLX)vsThermo Fisher Scientific Inc (TMO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Thermo Fisher Scientific Inc generates 1132% more annual revenue ($44.56B vs $3.62B). RLX leads profitability with a 25.5% profit margin vs 15.0%. RLX trades at a lower P/E of 21.6x. RLX earns a higher WallStSmart Score of 68/100 (B-).

RLX

Strong Buy

68

out of 100

Grade: B-

Growth: 7.3Profit: 6.0Value: 8.3Quality: 7.8
Piotroski: 5/9

TMO

Buy

59

out of 100

Grade: C

Growth: 4.7Profit: 7.0Value: 7.3Quality: 6.3
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

RLXUndervalued (+47.9%)

Margin of Safety

+47.9%

Fair Value

$4.68

Current Price

$2.21

$2.47 discount

UndervaluedFair: $4.68Overvalued
TMOSignificantly Overvalued (-27.5%)

Margin of Safety

-27.5%

Fair Value

$384.82

Current Price

$490.77

$105.95 premium

UndervaluedFair: $384.82Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RLX5 strengths · Avg: 9.8/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
46.8%10/10

Revenue surging 46.8% year-over-year

EPS GrowthGrowth
81.9%10/10

Earnings expanding 81.9% YoY

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Profit MarginProfitability
25.5%9/10

Keeps 26 of every $100 in revenue as profit

TMO3 strengths · Avg: 8.3/10
Market CapQuality
$182.14B9/10

Large-cap with strong market position

Operating MarginProfitability
21.2%8/10

Strong operational efficiency at 21.2%

Free Cash FlowQuality
$2.99B8/10

Generating 3.0B in free cash flow

Areas to Watch

RLX1 concerns · Avg: 3.0/10
Return on EquityProfitability
5.9%3/10

ROE of 5.9% — below average capital efficiency

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
1.764/10

Expensive relative to growth rate

P/E RatioValuation
27.6x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : RLX

The strongest argument for RLX centers on Price/Book, Revenue Growth, EPS Growth. Profitability is solid with margins at 25.5% and operating margin at 11.0%. Revenue growth of 46.8% demonstrates continued momentum.

Bull Case : TMO

The strongest argument for TMO centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : RLX

The primary concerns for RLX are Return on Equity.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

RLX profiles as a growth stock while TMO is a value play — different risk/reward profiles.

RLX carries more volatility with a beta of 1.23 — expect wider price swings.

RLX is growing revenue faster at 46.8% — sustainability is the question.

TMO generates stronger free cash flow (3.0B), providing more financial flexibility.

Bottom Line

RLX scores higher overall (68/100 vs 59/100), backed by strong 25.5% margins and 46.8% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

RLX Technology Inc

CONSUMER DEFENSIVE · TOBACCO · China

RLX Technology Inc., researches, develops, manufactures, distributes and sells e-vapor products in the People's Republic of China. The company is headquartered in Beijing, China.

Visit Website →

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Want to dig deeper into these stocks?